<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03185195</url>
  </required_header>
  <id_info>
    <org_study_id>AQX-1125-103</org_study_id>
    <nct_id>NCT03185195</nct_id>
  </id_info>
  <brief_title>Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125</brief_title>
  <acronym>ADME</acronym>
  <official_title>An Open-Label,2-Part Sequential Dose Study Designed to Assess the Absolute Bioavailability, Mass Balance Recovery, Metabolite Profile and Identification of Metabolite Structure for [14C]-AQX-1125 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aquinox Pharmaceuticals (Canada) Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aquinox Pharmaceuticals (Canada) Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to evaluate the absolute bioavailability, metabolism and elimination
      pathways of AQX-1125 in healthy male and female subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-centre, open-label, non-randomised, 2-part, sequential dose study in healthy
      male and female subjects. It is planned to enrol a single cohort of 8 healthy subjects (4
      male and 4 female) who will participate in Part 1 and Part 2 of the study.

      In Part 1, each subject will receive a single oral dose of AQX-1125 followed by an IV
      microtracer dose of carbon-14-AQX-1125 ([14C]-AQX-1125). In Part 2, each subject will receive
      a single oral dose of [14C]-AQX-1125.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 22, 2016</start_date>
  <completion_date type="Actual">January 4, 2017</completion_date>
  <primary_completion_date type="Actual">January 4, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open-Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute bioavailability (F) of AQX-1125</measure>
    <time_frame>0 - 96 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass balance recovery of total radioactivity in urine, faeces and all excreta</measure>
    <time_frame>0 -168 hrs</time_frame>
    <description>Measure amount excreted (Ae)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass balance recovery of total radioactivity in urine, faeces and all excreta</measure>
    <time_frame>0 -168 hrs</time_frame>
    <description>Measure Ae as a percentage of the administered dose (%Ae)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass balance recovery of total radioactivity in urine, faeces and all excreta</measure>
    <time_frame>0 -168 hrs</time_frame>
    <description>Cumulative recovery of Ae (Cum Ae)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass balance recovery of total radioactivity in urine, faeces and all excreta</measure>
    <time_frame>0 -168 hrs</time_frame>
    <description>Cum Ae expressed as a percentage of the administered dose (Cum %Ae)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite profiling and structural identification in plasma, urine and faeces to estimate the routes and rates of elimination of [14-C]-AQX-1125</measure>
    <time_frame>0 -168 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure Ae total radioactivity for urine and faeces</measure>
    <time_frame>0-168 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure %Ae total radioactivity for urine and faeces</measure>
    <time_frame>0-168 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure Cum Ae (total) for urine and faeces</measure>
    <time_frame>0-168 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure Cum% Ae (total) for urine and faeces</measure>
    <time_frame>0-168 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure PK parameters of total radioactivity in plasma following oral administration</measure>
    <time_frame>0 -96 hrs</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure PK parameters of total radioactivity in plasma following oral administration:</measure>
    <time_frame>0 -96 hrs</time_frame>
    <description>Tmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure PK parameters of total radioactivity in plasma following oral administration:</measure>
    <time_frame>0 -96 hrs</time_frame>
    <description>Tlag</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure PK parameters of total radioactivity in plasma following oral administration:</measure>
    <time_frame>0 -96 hrs</time_frame>
    <description>AUC (0-24)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure PK parameters of total radioactivity in plasma following oral administration:</measure>
    <time_frame>0 -96 hrs</time_frame>
    <description>AUC (0-last)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure PK parameters of total radioactivity in plasma following oral administration:</measure>
    <time_frame>0 -96 hrs</time_frame>
    <description>AUC (0-inf)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure PK parameters of total radioactivity in plasma following oral administration:</measure>
    <time_frame>0 -96 hrs</time_frame>
    <description>AUC % extrap</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure PK parameters of total radioactivity in plasma following oral administration:</measure>
    <time_frame>0 -96 hrs</time_frame>
    <description>lambda-z</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure PK parameters of total radioactivity in plasma following oral administration:</measure>
    <time_frame>0 -96 hrs</time_frame>
    <description>T1/2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure PK parameters of total radioactivity in plasma following oral administration:</measure>
    <time_frame>0 -96 hrs</time_frame>
    <description>CL/F</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure PK parameters of total radioactivity in plasma following oral administration:</measure>
    <time_frame>0 -96 hrs</time_frame>
    <description>Vz/F</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure PK parameters of total radioactivity in plasma following oral administration:</measure>
    <time_frame>0 -96 hrs</time_frame>
    <description>MRT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 1)</measure>
    <time_frame>0-96 hrs</time_frame>
    <description>Measurement of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 1)</measure>
    <time_frame>0-96 hrs</time_frame>
    <description>Measurement of Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 1)</measure>
    <time_frame>0-96 hrs</time_frame>
    <description>Measurement of Tlag</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 1)</measure>
    <time_frame>0-96 hrs</time_frame>
    <description>Measurement of AUC(0-24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 1)</measure>
    <time_frame>0-96 hrs</time_frame>
    <description>Measurement of AUC(0-last)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 1)</measure>
    <time_frame>0-96 hrs</time_frame>
    <description>Measurement of AUC(0-inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 1)</measure>
    <time_frame>0-96 hrs</time_frame>
    <description>Measurement of AUC%extrap</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 1)</measure>
    <time_frame>0-96 hrs</time_frame>
    <description>Measurement of lambda-z</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 1)</measure>
    <time_frame>0-96 hrs</time_frame>
    <description>Measurement of T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 1)</measure>
    <time_frame>0-96 hrs</time_frame>
    <description>Measurement of CL/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 1)</measure>
    <time_frame>0-96 hrs</time_frame>
    <description>Measurement of Vz/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 1)</measure>
    <time_frame>0-96 hrs</time_frame>
    <description>Measurement of MRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following IV administration (Part 1)</measure>
    <time_frame>0 - 96 hrs</time_frame>
    <description>Measurement of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following IV administration (Part 1)</measure>
    <time_frame>0 - 96 hrs</time_frame>
    <description>Measurement of Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following IV administration (Part 1)</measure>
    <time_frame>0 - 96 hrs</time_frame>
    <description>Measurement of Tlag</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following IV administration (Part 1)</measure>
    <time_frame>0 - 96 hrs</time_frame>
    <description>Measurement of AUC(0-24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following IV administration (Part 1)</measure>
    <time_frame>0 - 96 hrs</time_frame>
    <description>Measurement of AUC(0-last)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following IV administration (Part 1)</measure>
    <time_frame>0 - 96 hrs</time_frame>
    <description>Measurement of AUC(0-inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following IV administration (Part 1)</measure>
    <time_frame>0 - 96 hrs</time_frame>
    <description>Measurement of AUC%extrap</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following IV administration (Part 1)</measure>
    <time_frame>0 - 96 hrs</time_frame>
    <description>Measurement of lambda-z</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following IV administration (Part 1)</measure>
    <time_frame>0 - 96 hrs</time_frame>
    <description>Measurement of T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following IV administration (Part 1)</measure>
    <time_frame>0 - 96 hrs</time_frame>
    <description>Measurement of CL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following IV administration (Part 1)</measure>
    <time_frame>0 - 96 hrs</time_frame>
    <description>Measurement of Vz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following IV administration (Part 1)</measure>
    <time_frame>0 - 96 hrs</time_frame>
    <description>Measurement of VSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following IV administration (Part 1)</measure>
    <time_frame>0 - 96 hrs</time_frame>
    <description>Measurement of MRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessments based on adverse events, safety laboratory tests, vital signs, physical examinations, ECGs and AEs (Part 1)</measure>
    <time_frame>0 - 96 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 2)</measure>
    <time_frame>0 -168 hrs</time_frame>
    <description>Measurement of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 2)</measure>
    <time_frame>0 -168 hrs</time_frame>
    <description>Measurement of Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 2)</measure>
    <time_frame>0 -168 hrs</time_frame>
    <description>Measurement of Tlag</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 2)</measure>
    <time_frame>0 -168 hrs</time_frame>
    <description>Measurement of AUC(0-24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 2)</measure>
    <time_frame>0 -168 hrs</time_frame>
    <description>Measurement of AUC(0-last)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 2)</measure>
    <time_frame>0 -168 hrs</time_frame>
    <description>Measurement of AUC(0-inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 2)</measure>
    <time_frame>0 -168 hrs</time_frame>
    <description>Measurement of AUC%extrap</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 2)</measure>
    <time_frame>0 -168 hrs</time_frame>
    <description>Measurement of lambda-z</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 2)</measure>
    <time_frame>0 -168 hrs</time_frame>
    <description>Measurement of T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 2)</measure>
    <time_frame>0 -168 hrs</time_frame>
    <description>Measurement of CL/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 2)</measure>
    <time_frame>0 -168 hrs</time_frame>
    <description>Measurement of Vz/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 2)</measure>
    <time_frame>0 -168 hrs</time_frame>
    <description>Measurement of F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AQX-1125 in plasma following oral administration (Part 2)</measure>
    <time_frame>0 -168 hrs</time_frame>
    <description>Measurement of MRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure plasma whole blood concentration ratios for total radioactivity (Part 2)</measure>
    <time_frame>0 -168 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemical structure of major metabolites of [14-C]-AQX-1125</measure>
    <time_frame>0 -168 hrs</time_frame>
    <description>Major metabolites classified as &gt;10% of the AUC of total radioactivity in plasma and &gt;10% dose excreted in urine and faeces following oral administration (Part 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessments based on adverse events, safety laboratory tests, vital signs and ECG (Part 2)</measure>
    <time_frame>0 -168 hrs</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>AQX-1125 Oral Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AQX-1125 - Oral Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[14C]-AQX-1125 IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiolabelled AQX-1125 - Intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[14C]-AQX-1125 Oral Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiolabelled AQX-1125 - Oral Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AQX-1125 Oral Tablet</intervention_name>
    <description>Part 1: Subjects will receive a single oral dose of AQX-1125 followed by [14C]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive [14C]-AQX-1125 oral solution.</description>
    <arm_group_label>AQX-1125 Oral Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-AQX-1125 IV</intervention_name>
    <description>Part 1: Subjects will receive a single oral dose of AQX-1125 followed by [14C]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive [14C]-AQX-1125 oral solution.</description>
    <arm_group_label>[14C]-AQX-1125 IV</arm_group_label>
    <other_name>Radiolabelled AQX-1125 IV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-AQX-1125 Oral Solution</intervention_name>
    <description>Part 1: Subjects will receive a single oral dose of AQX-1125 followed by [14C]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive [14C]-AQX-1125 oral solution.</description>
    <arm_group_label>[14C]-AQX-1125 Oral Solution</arm_group_label>
    <other_name>Radiolabelled AQX-1125 Oral Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males

          -  Healthy females of non-child bearing potential

          -  BMI 18.0 to 35 kg/m2

        Exclusion Criteria:

          -  History of any drug or alcohol abuse in the past 2 years

          -  Regular alcohol consumption in males &gt;21 units per week and females &gt;14 units per week
             (1 unit = Â½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)

          -  Current smokers and those who had smoked within the last 12 months; this included
             cigarettes, e-cigarettes and nicotine replacement products. Positive cotinine test
             result at screening and each admission

          -  Clinically significant abnormal clinical chemistry, haematology, urinalysis or
             electrocardiogram (ECG)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr.Nand Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

